Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Frédéric Troalen"'
Autor:
Francoise Fouquet, Jia Min Zhou, Evelyn Ralston, Kerren Murray, Frédéric Troalen, Ella Magal, Olivier Robain, M. Dubois-Dalcq, Patrick Aubourg
Publikováno v:
Neurobiology of Disease, Vol 3, Iss 4, Pp 271-285 (1997)
The gene mutated in X-linked adrenoleukodystrophy (ALD), a progressive demyelinating disease, codes for a protein (ALDP) involved in very-long-chain fatty acid (VLCFA) transport. The expression of ALDP and of two peroxisomal enzymes involved in β-ox
Externí odkaz:
https://doaj.org/article/86226d97e6cb4bc894b6577f32e9a5fe
Autor:
Alexandre Perrier, Pierre Hainaut, Alexandre Guenoun, Dinh-Phong Nguyen, Pierre-Jean Lamy, Fabrice Guerber, Frédéric Troalen, Jérôme Alexandre Denis, Mathieu Boissan
Publikováno v:
Bulletin du Cancer. 109:170-184
Autor:
Alexandre Perrier, Pierre Hainaut, Pierre-Jean Lamy, Alexandre Guenoun, Dinh-Phong Nguyen, Fabrice Guerber, Frédéric Troalen, Jérôme Alexandre Denis, Mathieu Boissan
Publikováno v:
Bulletin du Cancer. 109:151-169
Autor:
Alexandre, Perrier, Pierre, Hainaut, Pierre-Jean, Lamy, Alexandre, Guenoun, Dinh-Phong, Nguyen, Fabrice, Guerber, Frédéric, Troalen, Jérôme Alexandre, Denis, Mathieu, Boissan
Publikováno v:
Bulletin du cancer. 109(2)
In oncology, the identification of targets that correlate with a type of cancer has led to a profound change in the notion of "tumor markers". Technological advances, in particular the development of high-throughput sequencing, have led to the emerge
Autor:
A. Laparra, Malik Berhoune, Christophe Massard, Cécile Cauquil, Stéphane Champiat, Benjamin Besse, Alexis Nolin-Lapalme, Caroline Robert, Christine Mateus, Charles Naltet, Frédéric Troalen, Olivier Lambotte, Stéphane Ederhy, Capucine Baldini, Aurélien Marabelle, Patricia Martin-Romano, Samia Hajem, Antoine Hollebecque, Jean-Marie Michot, P. Vuagnat
Publikováno v:
European journal of cancer (Oxford, England : 1990). 157
Aim Despite unprecedented results of anti-programmed death protein (ligand) 1 (PD-(L)1) immune checkpoint inhibitor in the oncology's armamentarium, immune-related adverse events (irAEs) represent a therapeutic hurdle. Currently, there is no consensu
Publikováno v:
ACS Sensors
ACS Sensors, 2019, 4 (10), pp.2786-2793. ⟨10.1021/acssensors.9b01420⟩
ACS Sensors, American Chemical Society, 2019, 4 (10), pp.2786-2793. ⟨10.1021/acssensors.9b01420⟩
ACS Sensors, 2019, 4 (10), pp.2786-2793. ⟨10.1021/acssensors.9b01420⟩
ACS Sensors, American Chemical Society, 2019, 4 (10), pp.2786-2793. ⟨10.1021/acssensors.9b01420⟩
International audience; The quantification of very low concentrations of circulating tumor DNA (ctDNA) biomarkers from liquid biopsies has become an important requirement for clinical diagnostics and personalized medicine. In particular, the simultan
Publikováno v:
ACS sensors. 4(10)
The quantification of very low concentrations of circulating tumor DNA (ctDNA) biomarkers from liquid biopsies has become an important requirement for clinical diagnostics and personalized medicine. In particular, the simultaneous detection of wild-t
Autor:
Clara Vazeille, Karim Fizazi, Christophe Massard, Laurence Albiges, Yohann Loriot, Frédéric Troalen, Bernard Escudier
Publikováno v:
Clinical Genitourinary Cancer. 14:e91-e93
Autor:
Antoine Hollebecque, P. Romano-Martin, Olivier Lambotte, S.S. Hajem, C. Robert, J-M. Michot, Stéphane Champiat, Christine Mateus, Frédéric Troalen, P. Vuagnat, Capucine Baldini, Andreea Varga, Christophe Massard, Cécile Cauquil, Stéphane Ederhy, M. Berhoune
Publikováno v:
Annals of Oncology. 30:v526
Background Anti-PD1 and anti-PD-L1 are effective checkpoints inhibitors to stimulate the immune system against many types of cancers. The flip side of these immunotherapies is the generation of immune-related adverse events (irAE), which can theoreti
Autor:
Sandra Berrafato, Xavier Sastre, François Lokiec, Brigitte Olichet, Frédéric Troalen, Thierry Bronzini, Keyvan Rezai, Stéphanie Saada
Publikováno v:
Annales de biologie clinique. 70:277-286
Le traitement par methotrexate haute dose necessite un suivi pharmacologique afin d’adapter les traitements de sauvegarde pour limiter les effets secondaires. L’etude realisee a ete menee afin de valider l’adaptation du reactif EMIT sur l’Uni